Bromide

Bromide

SCHEMBL4465616

Br.Fc1ccccc1-c1ccc(C23CCCN(CC2)C3)cn1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.37
CYP11B1 P15538 3/20 0.36
CYP11B2 P19099 2/20 0.36
GRM2 Q14416 1/20 0.35
IL4I1 Q96RQ9 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
RAB9A P51151 1/20 0.34
HSD11B1 P28845 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
NPY5R Q15761 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5222614 0.99 NPC1 (0.38) NPC1CYP11B1CYP11B2GRM2IL4I1
SCHEMBL2678187 0.96 NPC1 (0.39) NPC1CYP11B1CYP11B2GRM2IL4I1
SCHEMBL2677959 0.94 NPC1 (0.41) NPC1CYP11B1CYP11B2GRM2IL4I1
Bromide SCHEMBL4478970 0.84 NSD2 (0.32)
SCHEMBL5221954 0.83 NSD2 (0.32)
Bromide SCHEMBL4471147 0.82 HSD11B1 (0.39) HSD11B1NPY5R
SCHEMBL2679286 0.81 AKT1 (0.36) NPC1
SCHEMBL4463296 0.81 HSD11B1 (0.40) HSD11B1NPY5R
SCHEMBL2678934 0.80 CYP11B1 (0.41) CYP11B1CYP11B2L3MBTL1
Bromide SCHEMBL4558553 0.79 CNR2 (0.38) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585974-B2 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-08 US claimed
US-20070185137-A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2007-08-09 US claimed
EP-1465893-B1 DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2007-02-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185137-A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application PAICS, CYC1, AADAC NPC1 577/4885CYP11B1 136/4885CYP11B2 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.